UA66872C2 - Сполука, яка є памоатом оланзапіну або його сольватом, та спосіб лікування психотичних розладів - Google Patents
Сполука, яка є памоатом оланзапіну або його сольватом, та спосіб лікування психотичних розладівInfo
- Publication number
- UA66872C2 UA66872C2 UA2001032118A UA2001032118A UA66872C2 UA 66872 C2 UA66872 C2 UA 66872C2 UA 2001032118 A UA2001032118 A UA 2001032118A UA 2001032118 A UA2001032118 A UA 2001032118A UA 66872 C2 UA66872 C2 UA 66872C2
- Authority
- UA
- Ukraine
- Prior art keywords
- olanzapine
- solvates
- pharmaceutical compositions
- pamoate
- psychotic disorders
- Prior art date
Links
- IUDQMMSLVSVGDZ-UHFFFAOYSA-N chembl1201741 Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2.C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 IUDQMMSLVSVGDZ-UHFFFAOYSA-N 0.000 title abstract 3
- 239000012453 solvate Substances 0.000 title abstract 3
- 229960005017 olanzapine Drugs 0.000 title abstract 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 title abstract 2
- 229960001072 olanzapine pamoate Drugs 0.000 title abstract 2
- 208000028017 Psychotic disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000004005 microsphere Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16376898A | 1998-09-30 | 1998-09-30 | |
| US09/163,769 US6169084B1 (en) | 1997-09-30 | 1998-09-30 | 2-methyl-thieno-benzodiazepine formulation |
| PCT/US1999/006417 WO2000018408A1 (en) | 1998-09-30 | 1999-03-24 | 2-methyl-thieno-benzodiazepine formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA66872C2 true UA66872C2 (uk) | 2004-06-15 |
Family
ID=26859927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2001032118A UA66872C2 (uk) | 1998-09-30 | 1999-03-24 | Сполука, яка є памоатом оланзапіну або його сольватом, та спосіб лікування психотичних розладів |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP1119359B1 (enExample) |
| JP (1) | JP4551988B2 (enExample) |
| CN (1) | CN1146422C (enExample) |
| AT (2) | ATE359793T1 (enExample) |
| AU (1) | AU759751B2 (enExample) |
| BR (1) | BR9914156A (enExample) |
| CA (1) | CA2344873A1 (enExample) |
| CZ (1) | CZ302367B6 (enExample) |
| DE (2) | DE69935873T2 (enExample) |
| DK (2) | DK1468689T3 (enExample) |
| EA (1) | EA002580B1 (enExample) |
| ES (2) | ES2221376T3 (enExample) |
| GE (1) | GEP20094818B (enExample) |
| HK (1) | HK1041199B (enExample) |
| HR (1) | HRP20010238B1 (enExample) |
| HU (1) | HU227400B1 (enExample) |
| ID (1) | ID29574A (enExample) |
| IL (2) | IL141766A0 (enExample) |
| MY (1) | MY126476A (enExample) |
| NO (1) | NO328243B1 (enExample) |
| NZ (1) | NZ510208A (enExample) |
| PL (1) | PL196821B1 (enExample) |
| PT (2) | PT1119359E (enExample) |
| SK (1) | SK285944B6 (enExample) |
| TR (1) | TR200100885T2 (enExample) |
| TW (1) | TW577890B (enExample) |
| UA (1) | UA66872C2 (enExample) |
| WO (1) | WO2000018408A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1246827E (pt) * | 1999-12-28 | 2005-08-31 | Cipla Ltd | Novas formas polimerficas da olanzapina |
| US7022698B2 (en) | 1999-12-28 | 2006-04-04 | U & I Pharmaceuticals, Ltd. | Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof |
| PL196814B1 (pl) | 2002-05-17 | 2008-02-29 | Inst Farmaceutyczny | Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty |
| HU226410B1 (en) * | 2003-04-22 | 2008-11-28 | Egis Gyogyszergyar Nyilvanosan | Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them |
| US6987111B2 (en) * | 2003-08-06 | 2006-01-17 | Alkermes Controlled Therapeutics, Ii | Aripiprazole, olanzapine and haloperidol pamoate salts |
| EP1781666A1 (en) * | 2004-07-14 | 2007-05-09 | Shasun Chemicals and Drugs Limited | Improved process for making form i of olanzapine. |
| ES2253091B1 (es) * | 2004-07-27 | 2007-02-01 | Inke, S.A. | Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo. |
| EP2623095A1 (en) * | 2004-11-16 | 2013-08-07 | Elan Pharma International Limited | Injectable nanoparticulate olanzapine formulations |
| US20090155331A1 (en) * | 2005-11-16 | 2009-06-18 | Elan Pharma International Limited | Injectable nanoparticulate olanzapine formulations |
| EP1838716B1 (en) * | 2005-01-05 | 2011-06-01 | Eli Lilly And Company | Olanzapine pamoate dihydrate |
| CZ2006697A3 (cs) * | 2006-11-07 | 2008-05-21 | Zentiva, A. S. | Kompozice depotních olanzapinových injekcních systému |
| FR2927965B1 (fr) * | 2008-02-22 | 2010-06-04 | Valeo Materiaux De Friction Sa | Procede de fabrication d'un materiau de friction et notamment d'une couronne de friction d'embrayage. |
| JP5486690B2 (ja) * | 2009-11-16 | 2014-05-07 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | メラノコルチン受容体リガンドの医薬組成物 |
| WO2011091142A2 (en) * | 2010-01-20 | 2011-07-28 | Teva Pharmaceutical Industries Ltd. | Crystalline and amorphous forms of olanzapine pamoate |
| US9469630B2 (en) | 2010-10-18 | 2016-10-18 | Sumitomo Dainippon Pharma Co., Ltd. | Sustained-release formulation for injection |
| EP2956456B1 (en) | 2013-02-13 | 2017-07-12 | Neuland Laboratories Ltd | A process for preparation of olanzapine pamoate |
| CN105044231B (zh) * | 2015-06-27 | 2022-09-13 | 万特制药(海南)有限公司 | 一种分离测定奥氮平双羟萘酸盐一水合物有关物质的方法 |
| EP3600258A1 (en) | 2017-03-20 | 2020-02-05 | Teva Pharmaceuticals International GmbH | Sustained release olanzapine formulaitons |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA933134B (en) * | 1992-05-08 | 1993-11-30 | Akzo Nv | Depot preparation |
| EP0669128B1 (en) * | 1992-11-17 | 2000-01-05 | Yoshitomi Pharmaceutical Industries, Ltd. | Sustained-release microsphere containing antipsychotic and process for producing the same |
| TW376319B (en) * | 1993-04-28 | 1999-12-11 | Janssen Pharmaceutica Nv | Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine |
| EG23659A (en) * | 1995-03-24 | 2007-03-26 | Lilly Co Eli | Process and crystal forms of methyl-thieno-benzodiazepine |
| US5891461A (en) * | 1995-09-14 | 1999-04-06 | Cygnus, Inc. | Transdermal administration of olanzapine |
| AU720366B2 (en) * | 1996-09-23 | 2000-06-01 | Eli Lilly And Company | Olanzapine dihydrate D |
| AU752552C (en) * | 1997-09-30 | 2003-09-11 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine formulation |
-
1999
- 1999-03-24 AU AU33627/99A patent/AU759751B2/en not_active Expired
- 1999-03-24 ID IDW20010679A patent/ID29574A/id unknown
- 1999-03-24 PT PT99915009T patent/PT1119359E/pt unknown
- 1999-03-24 PT PT04005832T patent/PT1468689E/pt unknown
- 1999-03-24 HU HU0103636A patent/HU227400B1/hu unknown
- 1999-03-24 DK DK04005832T patent/DK1468689T3/da active
- 1999-03-24 GE GEAP199911232A patent/GEP20094818B/en unknown
- 1999-03-24 NZ NZ510208A patent/NZ510208A/xx not_active IP Right Cessation
- 1999-03-24 CZ CZ20011149A patent/CZ302367B6/cs not_active IP Right Cessation
- 1999-03-24 DE DE69935873T patent/DE69935873T2/de not_active Expired - Lifetime
- 1999-03-24 UA UA2001032118A patent/UA66872C2/uk unknown
- 1999-03-24 DK DK99915009T patent/DK1119359T3/da active
- 1999-03-24 ES ES99915009T patent/ES2221376T3/es not_active Expired - Lifetime
- 1999-03-24 EP EP99915009A patent/EP1119359B1/en not_active Expired - Lifetime
- 1999-03-24 DE DE69917663T patent/DE69917663T2/de not_active Expired - Lifetime
- 1999-03-24 AT AT04005832T patent/ATE359793T1/de active
- 1999-03-24 IL IL14176699A patent/IL141766A0/xx active IP Right Grant
- 1999-03-24 CA CA002344873A patent/CA2344873A1/en not_active Withdrawn
- 1999-03-24 TR TR2001/00885T patent/TR200100885T2/xx unknown
- 1999-03-24 CN CNB998115355A patent/CN1146422C/zh not_active Expired - Lifetime
- 1999-03-24 EA EA200100406A patent/EA002580B1/ru not_active IP Right Cessation
- 1999-03-24 PL PL346981A patent/PL196821B1/pl unknown
- 1999-03-24 ES ES04005832T patent/ES2285294T3/es not_active Expired - Lifetime
- 1999-03-24 AT AT99915009T patent/ATE267602T1/de active
- 1999-03-24 SK SK416-2001A patent/SK285944B6/sk not_active IP Right Cessation
- 1999-03-24 HR HR20010238A patent/HRP20010238B1/xx not_active IP Right Cessation
- 1999-03-24 WO PCT/US1999/006417 patent/WO2000018408A1/en not_active Ceased
- 1999-03-24 BR BR9914156-6A patent/BR9914156A/pt not_active Application Discontinuation
- 1999-03-24 HK HK02100774.0A patent/HK1041199B/en not_active IP Right Cessation
- 1999-03-24 JP JP2000571926A patent/JP4551988B2/ja not_active Expired - Lifetime
- 1999-03-30 MY MYPI99001217A patent/MY126476A/en unknown
- 1999-04-02 TW TW088105028A patent/TW577890B/zh not_active IP Right Cessation
-
2001
- 2001-03-01 IL IL141766A patent/IL141766A/en not_active IP Right Cessation
- 2001-03-28 NO NO20011583A patent/NO328243B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9813228A (pt) | Formulação de 2-metil-tieno-benzodiazepina | |
| HUP9900457A3 (en) | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents | |
| IL125735A (en) | Pharmaceutical compositions for the treatment of glaucoma comprising an inhibitor of serine-threonine kinase, tyrosine kinase or protein tyrosine phosphatase or an actin-disrupting compound | |
| WO1998033491A3 (en) | Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase | |
| ZA969001B (en) | Method compositions and kits for increasing the oral bioavailability of pharmaceutical agents | |
| AU3153097A (en) | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | |
| BG103190A (en) | Substituted pyrimidine derivatives and their pharmaceutical application | |
| IL161833A0 (en) | Pharmaceutical compositions and usethereof for thetreatment of psychotic diseases | |
| IL141766A0 (en) | 2-methyl-thieno-benzodiazepine formulation | |
| MXPA01001435A (es) | Composiciones farmaceuticas para la prevencion y tratamiento de trastornos del sistema nervioso central. | |
| HRP980163B1 (en) | Pharmaceutical composition for the oral administration of an n-piperidinopyrazole -3-carboxamide derivative, its salts and their solvates | |
| MX9704030A (es) | 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos. | |
| AU5309400A (en) | Methods and compositions for the treatment of neuroleptic and related disorders using sertindole derivatives | |
| GB2311940B (en) | Pharmaceutical compositions for the treatment of rhinitis | |
| BR9713215A (pt) | Formulação de partìcula revestida | |
| MX9708394A (es) | Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion. | |
| HUP9904030A3 (en) | Use of tiagabine for production of pharmaceutical against psychotic disorders | |
| AU686084B3 (en) | Pharmaceutical compositions for the treatment of depressive disorders | |
| EP0743068A3 (en) | Composition for inhibiting bone loss containing vanadyl sulfate | |
| AU6240999A (en) | Laminin 5 for treatment of bone defects | |
| AU6955998A (en) | Method for providing neuro-protective effects | |
| AP9600780A0 (en) | Process for the preparation of peroxetine hydrochloride anhydrate and its use as therapeutic agent. | |
| JO1909B1 (en) | Composition of 2-methylthenio-benzodiazepine oral |